HIV neutralization through use of antibodies and pharmacokinetics of topical applications by Chou, Chia-Wei Thomas
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2013
HIV neutralization through use of
antibodies and pharmacokinetics of
topical applications
https://hdl.handle.net/2144/12073
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
HIV NEUTRALIZATION THROUGH USE OF ANTIBODIES AND 
 
PHARMACOKINETICS OF TOPICAL APPLICATIONS 
 
 
 
 
by 
 
 
 
 
CHIA-WEI THOMAS CHOU 
 
B.S., University of California San Diego, 2009 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Arts 
 
2013 
ii 
   
Approved by 
 
 
 
 
 
 
 
 
 
First Reader   
Deborah Anderson, Ph.D. 
Professor of Obstetrics/Gynecology and Microbiology 
 
 
 
 
 
 
 
 
 
 
Second Reader   
Karen Symes, Ph.D. 
Associate Professor of Biochemistry 
 
  
 
 iii 
  
ACKNOWLEDGEMENTS  
 
I would like to thank Dr. Deborah Anderson for her guidance and support in this project, 
Dr. Manish Sagar and Dr. Jeffrey Pudney for their expertise relating to the work in this 
thesis, and the collective assistance of the lab. I would also like to thank Dr. Karen Symes 
for serving as my mentor throughout my master’s program. 
 iv 
HIV NEUTRALIZATION THROUGH USE OF ANTIBODIES AND 
PHARMACOKINETICS OF TOPICAL APPLICATIONS 
CHIA-WEI THOMAS CHOU   
 
Boston University School of Medicine, 2013 
 
Major Professor: Deborah Anderson, Ph.D., Professor of Obstetrics and Gynecology 
 and Microbiology 
 
ABSTRACT 
 
 The Human Immunodeficiency Virus Type 1 (HIV-1), a sexually transmitted 
retrovirus that causes the Acquired Immunodeficiency Syndrome (AIDS), infects over 
two million people a year. Several methods introduced to prevent HIV-1 transmission, 
such as condoms, circumcision and antiretroviral drugs, have proven to be partially 
effective, but more effective approaches are being sought. Topical microbicides are being 
developed to provide a women-controlled method to prevent the transmission of HIV-1. 
Unfortunately, most of the candidate microbicide compounds tested to date have either 
elicited undesirable mucosal inflammation and epithelial lesions leading to increased 
seroconversions, or have been ineffective. One novel approach currently being explored 
is the use of monoclonal antibodies as components of topical microbicides. Monoclonal 
antibodies can be produced inexpensively by transfection into Nicotiana plants. We 
hypothesize that anti-HIV monoclonal antibodies produced in Nicotiana (MAb-N) will be 
effective in neutralizing HIV- 1 when used as topical microbicides at mucosal sites, and 
set out to test whether they retain their efficacy under physiological conditions. We tested 
the pharmacodynamics of anti-HIV MAb-N efficacy in Cynomolgus macaques following 
application of the antibodies in the vaginal compartment. We further studied the ability of 
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MAb-N to cross through the vaginal epithelium using an EpiVaginal tissue model.  
 To determine the pharmacodynamics of HIV neutralizing activity after the 
application of anti-HIV MAb-Ns to the vaginal mucosa, we used a neutralization assay 
based on HIV-expression in the TZM-bl cell line to test the efficacy of various doses of 
MAbs in a time course after they had been administered intravaginally in gel form to 
Cynomolgus macaques. To determine the pharmacokinetics of Mab-N transport across 
the vaginal epithelium, monoclonal antibodies were added to the apical surface, and a 
human-IgG ELISA was used to detect Mab-N that had crossed the epithelium into the 
basal supernatant. Immunohistology was used to confirm and validate ELISA data for 
evidence of transfer of Mabs across the epithelial layer. 
 Our results show that anti-HIV MAb-Ns were effective in neutralizing cell-free 
HIV in TZM-bl neutralization assays. We found that MAb-Ns retained their anti-viral 
efficacy in monkeys after 4-hours. However, neutralizing activity was decreased after 24-
hours and 72-hours, with wide variability in effectiveness between individual macaques. 
Mab-ns tested in the EpiVaginal tissue model showed minimal transfer of antibodies 
across the epithelium, ranging from 0.005% to 0.09%. Immunohistological data showed 
that antibodies applied apically to tissue models concentrated only in the superficial 
layers of the stratum corneum and did not penetrate the epithelium. Our data indicate that 
anti-HIV MAb-Ns are effective in neutralizing HIV-1 following vaginal application for at 
least 4 hours, and that they do not pass through the vaginal epithelium in significant 
amounts. Our data support their further development as vaginal microbicides. 
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 1 
Introduction 
 According to UNAIDS, the joint United Nations program on HIV/AIDS, the 
Human Immunodeficiency Virus-type 1 (HIV-1) afflicts approximately 34 million people 
in the world as of 2011, with 2.5 million new cases of newly infected adults and children 
each year (UNAIDS, 2012). Based on the Global Report from UNAIDS, sub-Saharan 
Africa represents an endemic region consisting of 1.8 million of newly infected cases 
each year, followed by south and southeast Asia with approximately 200,000-300,000 
cases each year (UNAIDS, 2012). According to the World Health Organization (WHO), 
women account for half of the 7,000 new HIV cases that occur each day (Grammen, 
Augustijns, & Brouwers, 2012). It is necessary to continue to search for therapeutic 
solutions. However, in order to solve the issues that affect high-risk populations and 
endemic regions of HIV, improved prophylactic approaches must also be sought. This 
research explored the possibility of a prophylactic solution through the use of cost-
effective monoclonal antibodies produced in plants that can be used topically at mucosal 
sites to prevent transmission of HIV. 
 
The HIV virus and infection mechanism 
The virus is thought to have originated from monkeys in West Africa. HIV-1 is 
separated into three major groups that are designated M (main), O (outlier), and N (non-
M, non-O). Group M is subdivided into subtypes A to D, F1, F2, G to J, and K. Subtypes 
that originate from a common ancestor are then referred to as clades (Pier, Lyczak, & 
Wetzler, 2004). After initial infection with HIV-1, flu-like symptoms develop transiently; 
 2 
following the acute infection period, individuals can remain asymptomatic for periods of 
2-20 years before they develop symptoms of Acquired Immunodeficiency Syndrome 
(AIDS). 
HIV-1 is an enveloped retrovirus of the lentivirus group that contains two copies 
of RNA genome. As a retrovirus with an envelope acquired from host cell membranes, 
HIV is highly susceptible to environmental conditions that affect surface tension and as a 
result do not transfer through air, dust, or fomites (Ray, CG & Ryan, KG, 2010). Within 
the outer envelope, the virus contains a bullet-shaped capsid composed of the p24 
protein. Because the p24 protein is present in abundance in the virus, it is often used to 
test for positive infection of HIV through enzyme-linked immunosorbent assays or PCR 
(Pier et al., 2004). Lentiviruses were given their name due to their ability to persist in 
latent form in the host over lengthy periods of time. In the case of HIV, the cells affected 
tend to be those of the immune system. While affecting immune cells such as monocytes, 
macrophages, dendritic cells, Langerhans cells, and other immune cells, the most 
devastating infection occurs in the CD4 T cell which plays a major role in immune 
activation and immune response to bodily infections (Ray, CG & Ryan, KG, 2010).  
Entry of HIV into host cells occurs through direct fusion to the host cell 
membrane governed by the envelope protein complex of the virus. The presence of a 
precursor protein gp160 is cleaved by host cell enzyme furin leading to surface subunits 
of gp120 and a transmembrane subunit of gp41 (Chan & Kim, 1998). The gp41 and 
gp120 proteins exist on the virus surface as a trimer and are responsible for viral entry 
into target cells. They coexist with other complex-carbohydrate side chains that may also 
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serve a purpose in allowing the virus to evade immune system antibodies (Pier et al., 
2004). Binding of gp120 to target receptors leads to a conformational change of gp41 to a 
fusion-ready state for viral entry. The viral life cycle is like any other retrovirus in that 
virus envelope binds to receptors on target cells resulting in membrane fusion and entry 
of viral capsid. Viral RNA is then reverse transcribed to DNA and integrated into host-
cell genome ultimately using cellular machinery to produce viral RNAs and proteins. The 
virus is then packaged and assembled with host cell membrane and buds off (Pier et al., 
2004). 
HIV-1 infection requires CD4 receptors on target cell surfaces, but co-receptors 
such as CXCR4 and CCR5 must also be present in order to for fusion to be successful 
(Pier et al., 2004). The CCR5 coreceptor has been found to be important in early infection 
periods while CXCR4 corresponds to advancement of infection to AIDS (Ray, CG & 
Ryan, KG, 2010). Late-infection virions, can also use another coreceptor, CCR3. 
Interestingly, CCR5-deficient individuals have been observed to be highly resistant to 
infection even from repeated exposures to the virus suggesting it can be utilized as a 
possible therapeutic or prophylactic target (Pier et al., 2004). It has been found that HIV 
strains that utilize the CCR5 coreceptor can be blocked by a CCR5 ligand such as 
RANTES, which is released by activated CD8 T cells, while CXCR4 strains of HIV can 
be blocked with the corresponding SDF (stromal derived factor) ligand, an endogenous 
cytokine (Chan & Kim, 1998).  
HIV affects the human immune system by attacking the CD4 T cells. The 
destruction of CD4 T cells prevents the immune system from mounting adequate 
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defenses against infections thus leading to Acquired Immune Deficiency Syndrome 
(AIDS). Acute infection begins by transport of virus to lymph nodes by dendritic cells 
and Langerhans cells. Lymphocytes that cluster with infected dendritic cells become 
highly activated and undergo intense replication of HIV-1. There is a spike in viral 
replication that occurs 3-6 weeks after initial infection and virion count in the blood can 
reach millions per milliliter of blood. CD4 lymphocytes also rise in numbers to counter 
the infection. It is at this stage that 60% of people develop a non-specific response such 
as fever, pharyngitis, lymphadenopathy, headache, rash, nausea, or diarrhea. Antibody 
testing for HIV-1 during the earliest stage of infection is negative due to the delay in 
humoral response, but virus detection by p24 antigen ELISA or polymerase chain 
reaction (PCR) assay is possible. During the chronic asymptomatic infection stage, a 
steady-state equilibrium is reached between viral load and CD4 T-cell numbers in the 
blood. Over time the CD4 T cells decrease leading to late stage of infection, however, 
this chronic infection period can last many years (Pier et al., 2004). Specific events of the 
immune system following HIV infection include polyclonal B-cell activation, increased T 
cell turnover due to T cell activation, and increased levels of inflammatory and cytokines 
and chemokines in the blood serum (Douek, Roederer, & Koup, 2009). Although the 
immune system reacts as expected, immune activation of T cells promotes HIV 
replication in these cells, which leads to the production of more virus and T cell death. 
The high turnover rate of T cells leads to diminished pools of memory T cells and 
inflammatory damage of lymphoid tissues (Douek et al., 2009). The activation, infection, 
and loss of the central pool of memory CD4 T cells eventually progresses the disease 
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state to AIDS. At this late stage of infection, CD4 T cells rapidly decrease and viral loads 
increase. Once T cell counts drop below 200 cells per ul, opportunistic infections usually 
result in mortality (Pier et al., 2004). 
 
Transmission 
 Transmission of HIV generally occurs through sexual intercourse and maternal to 
fetal transmission. Other methods of HIV transmission include the sharing of needles by 
drug users, and infection of healthcare workers by needle sticks or exposure of mucosal 
surfaces to infected blood. Different routes of transmission have different infection rates. 
Vertical transmission from mother to the fetus or newborn carries a risk of 1 in 3, 
insertive rectal intercourse with an infected partner carries a risk of 1 per 100 exposures, 
while female-to-male heterosexual activity is lower at 1 per 1,500 (Pier et al., 2004). It 
has been found in non-human primate models (NHP) that HIV-1 can cross the mucosal 
barrier and establish populations of infected cells within hours (Haase, 2010). Virus then 
propagates from these founder populations continuing onto the secondary lymphoid 
tissue. Normally, vaginal secretions are acidic and can inactivate HIV; however, semen 
neutralizes the acidic pH environment of the vagina leading to potential infection at 
ectocervical, endocervical, and endometrial mucosal sites (Hladik & Doncel, 2010). HIV 
prevention strategies should focus on the initial phases of infection at the mucosal level 
(Haase, 2010). Exposure to virus causes recruitment of CCR6+ plasmcytoid dendritic 
cells, which then recruit macrophages and T cells, which in turn leads to growth of the 
infected founder cell population (Haase, 2011). Vaginal Langerhans cells and dendritic 
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cells are thought to play a role in ferrying infectious virions from the mucosa to 
lymphatic tissues (Hladik & Doncel, 2010). Trapping the virus in the mucus and physical 
mucosal barriers would therefore be a useful strategy. It is these recent findings that have 
suggested to researchers to begin looking at preventing transmission at the mucosal level 
at what is considered the window of opportunity to (neutralizing virus at time and 
location of exposure prior to infection). However, multiple difficulties must be overcome 
for strategies targeting the mucosa to work. These include the possibility of HIV 
disseminating too rapidly, or of HIV being carried within infected cells and therefore 
protected from the mucosal environment. 
     To date, circumcision has proven to be effective in decreasing female to male 
transmission by 50% to 60%, but vaccine and microbicide approaches targeting mucosal 
HIV transmission have largely been ineffective. The mucosal solutions must be able to 
penetrate through mucus and mucosal epithelium and retain activity in the mucosal 
environment. Microbicide concentration, molecular weight, hydrophobicity, release rate, 
surface area coverage, safety, and efficacy in presence of semen must all be taken into 
account for such an approach (Hladik & Doncel, 2010). Tenofovir, an antiretroviral drug 
that blocks reverse transcriptase, was the first microbicide compound to show significant 
efficacy in a clinical trial; it reduced HIV acquisition by 40% in a Phase IIb trial, with its 
efficacy related to drug compliance (Hladik & Doncel, 2010). 
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Antibodies 
 Antibodies play a major role in immune defense, especially the recognition and 
effector phases of humoral immunity against foreign antigens. Antibodies can activate the 
complement cascade, resulting in the lysis of target microbes, and can also block 
(neutralize) microbe function by binding to structural components such as receptors. 
Antibodies also play a role in a number of innate immune functions for elimination of 
pathogens including opsonization of antigens for phagocytic processing, and antibody-
dependent cell-mediated cytotoxicity in which antibodies target microbes for lysis by 
other immune cells.  
 
Figure. 1. General Antibody Structure. H denotes heavy chain and L denotes light 
chain. S-S denotes disulfide bonds. FC region denotes the crystallizable portion of an 
antibody, while Fab region denotes antigen-binding region. C denotes constant region. V 
denotes variable region (Abcam, n.d.). 
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As shown in Figure 1, the antibody has a symmetric structure with two light 
chains and two heavy chains. The light chain is attached covalently to a heavy chain with 
a disulfide bond while the two heavy chains are attached to each other with yet another 
covalent disulfide bond. Within the light and heavy chains are amino terminal variable 
regions that play significant roles in antigen recognition and carboxyl terminal constant 
regions that facilitate interaction of effector functions. Only the variable region’s constant 
regions are made up of three or four Ig domains, which comprise of 110 amino acid 
residues that fold globularly. Variable regions further consist of a heavy chain and a light 
chain that make up the antigen-binding site. Since there are two sets of variable heavy 
and light chains, each antibody contains two binding sites. Within the variable heavy and 
light chains are three hypervariable regions that are held in place by more conserved 
framework sequences. These three hypervariable regions are known as complementarity-
determining regions (CDRs). CDR3 is the most variable of the three hypervariable 
regions. These CDR regions have been shown through crystallographic analysis to extend 
from the surface of antibodies as loops to be able to interact with antigens. Thus sequence 
differences in the CDRs are responsible for the binding variability of antibodies. Another 
important structural distinction is the Fab (fragment, antigen binding) and Fc (fragment 
crystallizable). The Fab consists of just the variable light and heavy chain pair while the 
Fc fragment consists of the heavy chain regions together that are not attached to a light 
chain. The distinction is important as it leads to innovative approaches to neutralizing 
antibody research in which it is possible to use just the Fab without the Fc. 
 Antibody molecules are classified into isotypes IgA, IgD, IgE, IgG, and IgM. 
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Isotypes IgA and IgG in humans are further subdivided into subtypes IgA1, IgA2, and 
IgG1, IgG2, IgG3, and IgG4. IgA can be a monomer, dimer, or trimer, and IgM can be a 
pentamer, while IgE and IgG are monomers and IgD is found on the B-cell membrane. 
IgG has the longest half-life of all isotypes. IgG and IgA play an important role in 
mucosal immunity and are being considered as effector molecules in anti-HIV mucosal 
immune defense in the genital tract. 
 Two characteristics are critical to antibody neutralization of antigens, affinity and 
avidity. Affinity is the strength of binding of one antibody site to an antigen epitope. 
Avidity is the overall strength of attachment to the epitopes by the antibody. This is 
important in IgA and IgM isotypes as IgA can be a dimer or trimer while IgM can be a 
pentamer. Since avidity increases geometrically, IgM can have low affinity on its 
individual monomeric arms, but the overall avidity of the pentameric antibody can be far 
greater than monomeric binding (Abul K. Abbas & Andrew H. Lichtman, 2003). 
Developing antibodies against HIV-1 has been met with three major roadblocks. 
Important neutralizing sites are conformationally protected and thus unable to be 
targeted. For example, gp120, which is the viral protein responsible for binding to CD4 
on target cells, requires a CD4-induced conformational change in order for the binding 
site to be exposed. A second roadblock is the heavy glycosylation of gp120; surface sugar 
structures hide viral epitopes from the immune system. The third roadblock is the ability 
of HIV to rapidly mutate and escape the antibody response. In these ways, free virus can 
escape antibody defenses and sustain a latent infection for long periods of time (Pier et 
al., 2004). 
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Immune Response 
 Antibodies take advantage of various mechanisms to neutralize foreign bodies 
often utilizing the Fc region of the antibody. These mechanisms include effector 
functions such as recruiting B cells, dendritic cell, natural killer cells, macrophages, mast 
cells, and monocytes. Recruitment of these cells further activates or inhibits functions 
that can release cytokines; induce granulation, phagocytosis, or oxidative effects. In turn 
these effector functions can activate the complement system of proteins as well as 
mannose binding lectin proteins, which result in initiation of the antibody-dependent 
cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis mechanisms. 
Antibody-dependent cell-mediated viral inhibition has also been used as a term to 
describe situations in which antibodies result in decreased viral loads. Again they take 
into account the previously mentioned mechanisms of immune response. Fc domains 
itself also interact with FcR’s (Fc Receptors) which dictate immune response. Besides the 
typical variables such as titer, affinity, avidity, specificity and polyclonality of antibodies 
present, glycosylation of Fc domains play a major role in interactions with FcRs. There is 
also variability in effector function dictated by which immunoglobulin’s bind. For 
example, IgG1 and IgG3 are able to activate complement and bind all FcR’s, but IgG2 
activates complementation and binds only some FcγR2 genotypes. IgG4 interacts with 
only FcγR and but does not activate complementation (Ackerman, Dugast, & Alter, 
2012). These distinctions could play a significant role in harnessing antibodies to prevent 
the transmission of HIV-1. 
In HIV-specific immune responses, anti-p24 IgG1 is the first significant antibody 
 11 
to develop. Anti-gp120 IgG3 is the other significant antibody to develop during early 
infection. Approximately 2 weeks after infection, antibodies to gp41 are also observed. 
These neutralizing antibodies (nAbs) must constantly adapt to changes in the viral 
envelope. True broadly neutralizing antibodies (bnAbs) that are able to neutralize a wider 
range of virus do not form until after years of seroconversion (Ackerman et al., 2012). 
Recruitment of natural killer (NK) cells that can recognize virus-infected cells leads to 
elimination of HIV-infected targets by ADCC. Unfortunately, NK cell activity becomes 
weaker with progressing viral infection. ADCC has been studied as a mechanism that 
decreases viral load in the acute phase of infection. Other studies have considered the role 
of ADCC in the course of HIV infection. A study by Baum, et al. at the Multicenter 
AIDS Cohort Study showed rapid disease progression resulted in lower ADCC against 
cells coated with gp120 antibodies (Forthal & Moog, 2009). These results, however, were 
not consistent with other studies, and in the case of the VAX003 HIV vaccine trial 
lowered ADCC activity was not observed. Macrophages can phagocytose and eliminate 
opsonized (antibody-coated) HIV without antigenic recognition; however, macrophages 
of the CD14+, FcγR3+ subset are themselves vulnerable to HIV infection leading to 
long-lasting viral reservoirs. HIV is also known to change phagocyte structure and 
function due to loss of FcγR3 and this is speculated to be the cause of decreased 
antibody-dependent cellular phagocytosis (ADCP) function. It is the ADCP mechanism 
that allows antibody-opsonized material to be cleared regardless of direct cytotoxicity. Fc 
receptors themselves play a role in the HIV immune response. Polymorphisms of Fc 
receptors such as FcγR2a have been shown to correlate with HIV disease progression. 
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Another type of antibody-dependent immune response to HIV infection is antibody 
dependent cell-mediated virus inhibition (ADCVI). This mechanism is similar to ADCC 
and ADCP in that it relies on an antibody and effector cell relationship, but ADCVI 
activity is measured by impact on viral production by target cells. Cells engaged in 
ADCVI can directly lyse HIV-infected target cells, or release antiviral cytokines such as 
Beta-chemokines. Studies have found ADCVI antibodies to have an inverse relationship 
with plasma viremia, indicating that they may play a role in viral control in vivo (Forthal 
& Moog, 2009). 
Mucosal surfaces provide a physical barrier to viral infection, and can also mount 
specialized immune defense mechanisms. Since genital and rectal mucosal surfaces are 
the most common sites of HIV transmission, much thought has been dedicated to 
generating protective mucosal immune responses. Studies by Hur et al, have shown that a 
polymeric IgA form of anti-HIV antibody (the type of IgA that is found in mucosal 
secretions) can inhibit HIV mucosal transmission with greater effectiveness than 
monomeric IgA or IgG. It has been suggested by recent data that HIV polyclonal 
antibodies in conjunction with mucus trapping and immobilizing offer better results than 
mAbs. It is logical that polyclonal antibody would be better suited for this purpose by 
forming multivalent aggregates more easily (Ackerman et al., 2012). Hur et al 
transplanted human hematopoietic stem/progenitor cells with an anti-HIV b12-IgA 
bnmAb gene into a humanized bone marrow-liver-thymus (BLT) mouse model. These 
mice were protected from virus-mediated depletion of CD4 T cells after HIV-1 challenge. 
One reason why IgA performs favorably at mucosal sites is that polymeric IgA (pIgA) is 
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transcytosed from the lamina propria to the mucosal lumen by a polymeric 
immunoglobulin receptor (PIGR) found on mucosal epithelial cells (Hur et al., 2012). 
Studies have also been carried out to study the neonatal Fc receptor FcRn in its role in 
mucosal immune response. FcRn has been found in the epithelial cells of the human 
intestine, lung, kidney, nasal, vaginal and rectal tissue and is capable of transporting Ig-G 
associated antigens across polarized epithelial barriers. It has also been observed to 
transport IgG across epithelial barriers in both human placenta and neonatal intestines in 
rodents to transfer passive immunity from mother to fetus (Yoshida, 2006). It has been 
speculated that FcRn could bidirectionally transport IgG between apical and basal 
environments, and tests have shown FcRn-deficient mice become susceptible to 
infections by C. rodentium, a bacterial pathogen similar to E. coli in humans (Yoshida, 
2006). FcRn may also affect HIV infection at mucosal sites by transporting IgG to the 
mucosal surface, and transporting HIV-IgG immune complexes across the mucosa into 
the lamina propria they could infect or sensitize immune cells. Ye et al, were able to 
protect mice that were challenged with herpes simplex virus type-2 (HSV-2) by 
mimicking IgG transfer at mucosal surfaces through fusing of an IgG Fc fragment with 
an adjuvant CpG. The Fc fragment was attached to an HSV-2 major envelop glycoprotein 
and delivered by FcRn to instill both humoral and cellular immunity (Ye, Zeng, Bai, 
Roopenian, & Zhu, 2011). The research additionally showed that FcRn knockout mice 
that were treated with the glycoprotein-fused IgG were unable to fend off lethal doses of 
HSV-2 suggesting FcRn as crucial to this novel vaccine delivering mechanism (Ye et al., 
2011). Therefore, the approach to antibody design against the HIV-1 virus must take into 
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account the multitude of variables arising from the antibodies themselves and their 
interactions with immune response effector functions, particularly those relating to Fc-
FcγR interactions. 
 
Current Research Related to this Project 
 There is constant work towards a vaccine for HIV that acts by inducing antibodies 
in a way similar to vaccines for other viral diseases such as influenza, measles, or polio. 
However, methods of testing antibody responses capable of neutralizing HIV continue to 
be difficult. HIV neutralization assays have numerous variables that can affect the 
outcome of the test, such as target cell line, density of plated cells, viral dose, antibody 
dose, duration of infection, cell free virus incubation time, quantitative endpoints and 
others (Polonis et al., 2008). Early neutralization assays used T-cell line-adapted (TCLA) 
viruses; virus and antibody were incubated together and then added to CD4+ target cells. 
Multinucleated cells and cell survival was then quantified to determine whether the virus 
was neutralized, however, results from such assays proved to be unreliable (Polonis et al., 
2008). Assay design turned towards use of peripheral blood mononuclear cells (PBMC) 
from human donors which hopefully would give results in a more physiological context, 
however, human donors have different susceptibility to HIV-1 infection. Variability in 
PBMC infectability resulting from donor genetics could be attributable to CD8+ and 
CD4+ variability along with genetic polymorphism differences in CCR5 and other 
chemokine receptors. Added to this was inter-experiment and inter-lab variability in 
PBMC-based neutralization assays (Polonis et al., 2008). More recent approaches to 
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testing virus neutralization with antibodies have used “pseudoviruses” that have a cloned 
HIV-1 envelope gene into defective virus particles resulting in virus that is capable of 
only one round of infection. These viruses are then used to test antibody neutralization 
using the epithelial HeLa cell line (TZM-bl) that is genetically modified to express the 
CD4, CCR5, and CXCR4 receptors as well as a β-galactosidase reporter gene allowing 
quantification of infection through spectrometry (Polonis et al., 2008) Table 1 shows the 
comparison of current approaches in HIV neutralization assays and their differences. It 
has been noted that TZM-bl cells have a higher CD4:CCR5 ratio (1:2) compared to 
PBMCs (1:20), which can also be a factor in the neutralization assay. Comparisons 
between neutralization assays using TZM-bl vs. PBMC target cells often show divergent 
results. For example, the 4E10 mAb has much broader neutralizing activity in the TZM-
bl assay than in the PBMC assay. The TZM-bl assay is thought to offer a more uniform 
method to study inhibition of binding and entry of HIV. However, some studies have 
shown that a high proportion (up to 85%) of HIV entry into TZM-bl cells occurs as 
endocytosis which may not be physiological (Polonis et al., 2008). Most TZM-bl assays 
also include the use of DEAE-dextran which increases HIV entry into endosomal vesicles 
(Polonis et al., 2008). The endosomal entry issue is not relevant however in the study of 
bnmAbs, as HIV is inactivated in the endosomes. It is the virus that is not neutralized and 
infects the cells via surface receptors that is measured by the quantitative assay endpoint. 
The TZM-bl HeLa cell model thus has evolved as the gold standard neutralization assay 
to determine effectiveness of bnmAbs (Gilbert et al., 2010).  
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Table 1. Comparison of HIV neutralization assay using PBMC and TZM-bl 
Assay PBMC TZM-bl (JC53-bl) 
Cells PBMC Epithelial HeLa 
Virus Uncloned primary Pseudovirus 
Assay length 4-6 days 2-3 days 
Common endpoint Extra- or intra-cellular p24 Luciferase activity 
Rounds of infection Multiple or Single Single 
DEAE-dextran used No Yes 
Measure inhibition of 
attachment/entry 
Yes Yes 
Cell-cell transmission Potentially No 
Coreceptors used CCR5, CXCR4, others 
(CCR5 physiologic) 
CCR5, CXCR4 (>2 logs 
more CCR5 than PBMC) 
(Polonis et al., 2008) 
 
Current Pharmacologic Therapies 
  Early HIV-1 therapeutic agents such as zidovudine acted as nucleoside analog 
inhibitors of reverse transcriptase. These were unsuccessful in in vivo experiments, and 
increases in CD4 cell counts in patients were short lived. Combination therapy was 
introduced in the mid-1990’s, which proved to be highly successful. Nucleoside analogue 
inhibitors terminated chain formation during reverse transcriptase, which would lead to 
depletion of intracellular nucleotides. While nucleoside reverse transcriptase inhibitors 
used individually resulted in high mutation to resistance, when used in combination with 
purine or pyrimidine analogues, protease inhibitors, and non-nucleoside reverse 
transcriptase inhibitors, resistance was avoided and effectiveness was increased. Non-
nucleoside inhibitors targeted the early viral infection phase by preventing pro-viral DNA 
production while protease inhibitors targeted the viral protease necessary for processing 
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viral precursor proteins. In such a way, they interfered with viral replication in late stages 
of its life cycle (Pier et al., 2004).  
 
Vaccine development efforts and broadly neutralizing monoclonal antibodies 
  Past efforts to develop an HIV vaccine have for the most part failed. An early 
strategy that focused on eliciting an antibody response using monomeric gp120 particles 
as immunogens produced antibodies that neutralized laboratory strains of HIV that had 
those specific gp120 monomers, but not primary isolates of virus (Chan & Kim, 1998). 
Furthermore, antibody responses to gp120 were generated by linear epitopes which are 
not as effective and ideal as physiologically significant tertiary structure epitopes of 
gp120 (Chan & Kim, 1998). Other methods of vaccine generation included reverse 
vaccinology, using crystallographic structure of broadly neutralizing monoclonal 
antibodies (bnmAbs) that could bind to HIV-1 epitopes, however epitopes used to 
stimulate bnmAbs were found to be ineffective (Regenmortel, 2012). Specific epitopes 
that have had some promise and continue to be explored include the membrane proximal 
external region (MPER) of gp41, which bnmAbs 2F5, 4E10, and Z13e1 have shown to 
bind to (Hessell et al., 2009). Thus MPER has been pursued as a likely candidate for 
design as an immunogen.  
 
Other Prophylactic Approaches 
 Another biopharmaceutical approach for HIV prevention has been the use of 
topical microbicides. The earliest research in this area explored the idea of non-specific 
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anti-HIV microbicides. Attempts at topical microbicides included Nonoxynol-9, Savy®, 
Carraguard®, cellulose sulfate, PRO-2000, and Buffergel®, all of which reached phase 3 
clinical trials but failed (Grammen et al., 2012). Nonoxynol-9 caused cytokine release, 
immune cell recruitment, and changed vaginal flora while also increasing epithelial 
lesions (Adams & Kashuba, 2012). Savvy® disrupted the envelope membrane of HIV, 
and was thought to be less toxic than Nonoxynol-9 but both drugs showed more 
seroconversions in treatment than placebo arms. Likewise cellulose sulfate also showed 
more seroconversion with use than placebo arms (Adams & Kashuba, 2012). The other 
nonspecific compounds tested, Buffergel®, PRO2000®, and Carraguard®, were unable 
to show significant efficacy in trial studies (Adams & Kashuba, 2012). These nonspecific 
microbicides have thus proven to be ineffective and even dangerous as methods of HIV 
prevention (Whaley et al., 2010). Other approaches to topical HIV prevention have 
included the study of RC-101, retrocyclin peptide 1, a peptide analogue from the defensin 
group of proteins that is able to prevent HIV binding to CXCR4 and CCR5 receptors. The 
RC-101 peptide has been shown to be promising in macaque challenges and studies of it 
continue (Adams & Kashuba, 2012). Another promising microbicide candidate has been 
recombinant RANTES, which has successfully worked in macaques to protect against 
vaginal SHIV challenges; however it has been difficult to produce in sufficient quantities 
(Whaley, Hanes, Shattock, Cone, & Friend, 2010). Recombinant RANTES maintains 
stability at 55-degree Celsius for > 1 month in HEC gel, and is also stable under 
conditions found in the vaginal environment such as low pH. It is suggested that 
recombinant RANTES could be incorporated into IVR devices (Whaley et al., 2010). 
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Recombinant antibodies have also been explored due to their specificity, potency, and 
safety profile. Nanoparticles have been explored as well in hopes of achieving sustained 
drug release for periods longer than a day, however, with the presence and turnover of 
mucus in vaginal environments, one would not expect nanoparticles to penetrate the 
mucus let alone reach the epithelium (Whaley et al., 2010). It was discovered that the 
average pore size of cervical vaginal mucus is 340 ± 70nm, which is far greater than the 
size of HIV particles (Lai, Wang, Hida, Cone, & Hanes, 2009). It has also been observed 
that HIV-1 adheres to mucus at pH 4; however, when the vaginal environment is 
neutralized by semen, HIV-1 can readily diffuse through the mucus (Lai et al., 2009). 
This presents the case for development of mucus-penetrating compounds that can provide 
protection against HIV within and under the mucus coat.  
           Research has shifted from non-specific topical microbicides to smaller molecular 
antiretroviral (ARV) drugs that can be applied at tissue sites of possible transmission 
such as the vaginal mucosa (Adams & Kashuba, 2012). No matter if the approach is ARV 
or non-specific microbicides, the pharmacokinetics of drug application to mucosal tissues 
have been difficult to study. The ARV tenofovir has been tested as a gel and from 
measurements of interleukin-8 (an indicator of inflammation), data suggests it is well 
tolerated by the tissue (Kiser et al., 2012). Data from the first large clinical trials 
conducted [the Chemoprophylaxis for HIV Prevention in Men study (iPrEx) and Partners 
PrEP studies] using tenofovir to prevent transmission showed modest effects. Tenofovir 
was able to reduce HIV risk compared to a placebo by 67 percent with daily use 
(Marrazzo et al., 2013). However, subsequent studies have been less successful primarily 
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due to poor compliance in the study population (Marrazzo et al., 2013). This suggests that 
approaches such as vaginal rings that deliver microbicides for longer periods of time may 
provide a better solution to prevent HIV transmission in the populations of the endemic 
regions. 
 
Monoclonal Antibodies 
 Initially, select bnMAbs were isolated from sera of HIV-1 infected individuals 
and screened against HIV in hopes of designing an effective antibody based vaccine with 
broadly neutralizing capabilities at low concentrations (Laura M. Walker et al., 2011). 
The use of high throughput neutralization screening resulted in bnMAbs targeting an 
epitope on the envelope protein that spans conserved regions of variable loops on the 
gp120 protein (L. M. Walker et al., 2009). Early bnMAbs such as b12 isolated in 1992 
from a phage display library database was able to neutralize 40% of known HIV-1 
isolates (Wu et al., 2010a). Data from Walker et al., identified two bnMAbs, PG9 and 
PG16, which specifically bound to trimeric Env targets suggesting another target epitope 
for immunogen design, or at least an additional bnMAb to consider in alternative 
therapeutic approaches. Both PG9 and PG16 offer more insight into vaccine immunogen 
design due to their possible potency against non-clade B viruses. Non-clade B viruses 
make up a large percentage of infections outside North American and Europe where 
treatments are lacking. Two other well-known bnMAbs are 2F5 and 4E10, which are 
known to act on the MPER region of the gp41 coreceptor (Stamatatos, Morris, Burton, & 
Mascola, 2009). The antibodies 2F5 and 4E10 were originally IgG3 antibodies collected 
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from a HIV-1 seropositive asymptomatic patient. They were then modified in hybridomas 
to IgG1 for longer shelf life and future scalability reasons (Hessell et al., 2009). In the 
studies of Hessell et al., mabs 2F5 and 4E10 provided complete protection against SHIV 
infection challenges in rhesus macaques. The 4E10 bnMAb has been shown to be 
neutralizing across clades at a moderate potency thus suggesting limitations to its 
effectiveness as a prophylaxis or target for immunogen design (Binley et al., 2004). 
However, according to more recent data, the 4E10 antibody is highly efficient at 
inhibiting cell-to-cell viral spreading via mature dendritic cells (Sagar et al., 2012). 
Finally, another promising bnMAb is VRC01, which targets CD4 binding sites of HIV 
thus allowing it to be effective in neutralization (Zhou et al., 2010). VRC01 has been 
shown to neutralize approximately 90% of viral particles suggesting it can be used as a 
template to further develop more effective versions of bnMAbs (Zhou et al., 2010). In 
Zhou et al, out of 190 circulating HIV-1 isolates tested for neutralization by VRC01, 173 
were neutralized and 17 were found to be resistant. The potency of VRC01 is attributed 
to its interaction with gp120 in a way that mimics CD4, the cell receptor crucial to HIV-1 
cell entry (Wu et al., 2010b).  VRC01 has served as a template for rational design of 
improvements. This has resulted in the development of NIH45-46, a VRC01 variant of 
increased potency (Diskin et al., 2011). Some of the differences that have made NIH45-
46 more potent include a tyrosine at position 74, a tyrosine to serine substation in 
constant domain region L1, and a four-residue insertion in constant domain region H3 
(Diskin et al., 2011). It remains to be seen whether NIH45-46 can be used to further 
develop more potent bnMAbs for use as prophylaxis or to generate possible targets for 
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immunogen design. Like combination anti-retroviral therapy, various different bnMAbs 
are likely to be used in combination with each other for maximum effectiveness. 
Taking into consideration HIV-1’s ability to evolve rapidly against full-sized 
antibodies, it has also been hypothesized that mAb approaches may be more effective 
using smaller antibody fragments. This approach would use fragments 11-15kDa in size 
which would enable binding to hidden epitopes while maintaining good penetrative 
properties (Chen & Dimitrov, 2011). Naturally the next step in bnmAb design is the 
combination of multiple bnMabs to increase the potency and longevity of such a 
treatment. Already studied in vivo, a 10mg/kg dose of a bi-functional fusion inhibitor 
dose of anti-CD4 mAb’s has been shown to maintain a 2000-fold serum concentration 
over IC90 for a week. This suggests that when combined, a cocktail of such mAbs would 
be effective and have favorable pharmacokinetic characteristics (Chen & Dimitrov, 
2011). Of course the main barriers to HIV-1 therapy has always been the virus’ 
evolutionary capabilities. Oral pharmaceutical approaches have always been favored 
because of the relatively low costs of production as well as ease of drug administration, 
despite the toxicities of long-term use of pharmaceuticals. The cost of mAb production 
has always been a significant barrier as well. 
 
Monoclonal Antibody Production 
 Current methods of producing monoclonal antibodies begin with the 
immunization of a mouse model, retrieving immune cells from the spleen, and creating 
hybridomas by combining the immune cell and cancer cell to create an immortal antibody 
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producing cell line (Marrazzo et al., 2013). Once the cell line is obtained, two methods 
are used to produce mAbs. One way is to clone the cell in-vitro, in culture. The second 
method is to inject the hybridoma cells into the peritoneal cavity of a mouse where the 
hybridoma multiplies and produces ascites (fluids) containing large amounts of the 
antibody (National Academy Press, 1999). Harvesting mAbs from ascites comes with its 
own difficulties. Ascites mAb production takes a long time and there is considerable 
variability of titers based on production abilities of individual mice. Ascites-produced 
mAbs may contain mouse proteins and other contaminants requiring costly purification 
steps. The physical costs of a mouse facility are also often overlooked as an important 
expense. Ascite production requires daily monitoring of mice to determine when a mouse 
should be euthanized to limit stress. The Institutional Animal Care and Use Committee 
(IACUC) have many recommendations in proper procedures for ascite harvesting. 
Overall animal welfare is of high priority as mice must be monitored for changes in 
behavior, appearance, body weight, temperature, clinical signs and so on (National 
Academy Press, 1999). Such procedures have increased costs of mAb production. In-
vitro methods have their own issues as well. Hybridoma cells vary in their ability to 
survive in-vitro environments, and the equipment needed for commercialization is costly. 
Fetal bovine serum is used in most culture media but can contain bovine immunoglobins, 
which can contaminate mAb preparations. This has led to the development of serum-free 
culture media but not without its own issues. Serum-free media increases hybridoma in-
vitro adaptation time by 3%-5% because of the increase in cell passages and sometimes 
hybridomas never adapt to in-vitro environments (National Academy Press, 1999). In-
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vitro culture methods can also sometimes produce mAbs that gain or lose sites of 
glycosylation (National Academy Press, 1999). 
 Commercial sources currently produce mAbs for diagnostics and therapeutics. 
The main method of mAb generation by the industry is through in-vitro technology with 
serum-free media due to therapeutic requirements of very pure and uncontaminated 
mAbs. They are usually produced in small batches, which is quicker than large-scale 
production, but costlier. Large-scale production is less expensive but requires more time 
investment (National Academy Press, 1999).  
        Initial industrialization of MAb production in 1986 resulted at first in low yields of 
1g/L but has since achieved yields of up to 5g/L, which in terms of a 10kL – 25kL 
bioreactor would equate to 15-100kg of product (Kelley, 2009). According to industry 
averages, however, even with increased yields MAbs remain an expensive product as cost 
per gram begins at a minimum of $2,000 per gram with a median of $8,000 and up to 
$20,000 per gram (Kelley, 2009). MAbs are clinically used at concentrations of 10-15 mg 
per kg thus leading to high production costs in the clinical realm (Ma et al., 2005). 
         Complications and inefficiencies of current methods of mAb production have led 
research to explore the possibilities of plant-based models of monoclonal antibody 
generation. Manufacture of such mAbs has made use of Agrobacterium as a vector for 
primary infection of plant based models. The tobacco mosaic virus has also been used in 
Nicotiana models for mAb production (Hiatt & Pauly, 2006).  
One advantage of plant-based MAb production is the range of products 
producible in plants. Plants as eukaryotes, are able synthesize small peptides, 
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polypeptides, and complex multimeric proteins that are not possible in microbial 
solutions. Furthermore, plant chaperones are analogues to mammalian versions and 
targeting of similar excretory pathways can result in control of glycosylation as well (Ma 
et al., 2005).  
Of course with any transgenic-based model, there is risk of inadvertent 
introduction to the wild. The plant-based model’s routine use of green houses can 
physically minimize such incidents, as well as the use of specific male-sterile plant lines. 
Seed dispersal is also controlled by making seed viability dependent on exogenous 
stimulation to seed germination (Ma et al., 2005). Recent research has looked into the 
development of MAbs using plant-based models with the pursuit of increased yield being 
an important driving factor (Ma et al., 2005). Previous plant models using common 
species such as corn faced issues of long life cycles with low yields and also requiring 
acres of environmental containment to prevent genetic contamination (Hiatt & Pauly, 
2006). More recently, research has taken advantage of the Agrobacterium-mediated viral 
infection model of tobacco plants to produce full-sized IgG antibodies in less than two 
weeks with yields of 0.5 g of mAb per kg of plant biomass. Initial plant production of 
heterooligomeric antibodies met difficulties due to the natural ability of plants to defend 
against viral infection through exclusion of viral genome (Hiatt & Pauly, 2006). The 
techniques used to produce the antibodies used in experiments carried out in this paper 
take advantage of Nicotinia-based manufacturing pioneered by Mapp Biopharmaceuticals 
Inc. This model benefits from high yields using transient viral expression to output high 
amounts of mAbs as well as using a plant model with genetically modified glycosylation 
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pathways to produce antibodies with mammalian glycoforms (Whaley, Hiatt, & Zeitlin, 
2011). The Nicotiana model is scalable without requiring the need to change 
environmental conditions and because the viral genome is not encoded into the plant 
pollen, there is no risk of spread of recombinant genes (Whaley et al., 2011). This 
technique has led to the production of mAbs such as 2G12 that are indistinguishable from 
mammalian cell-derived derived 2G12. It is estimated that plantibodies can be produced 
for use in microbicides at a cost of less that one US dollar for a dose of 10mg of purified 
protein (Whaley et al., 2011). Thus this approach could provide an inexpensive and 
effective method to prevent HIV transmission in developing countries with a high 
prevalence of HIV.   
 
Specific Aims. 
(1) Assess the effectiveness of broadly neutralizing antibodies against HIV produced by 
the Nicotiana plant species on HIV infection in the TZM-bl HeLa cell model 
(2) Determine the time course of mAb neutralizing activity in the vaginal environment 
(3) Study transport of nMabs across the vaginal epithelium 
 The study is expected to: 
(1) Provide further insight on the effectiveness of broadly neutralizing antibodies 
produced by plants against HIV.  
(2) Show time course and duration of efficacy of plantibodies in vaginal secretions of 
Cynomolgus macaques 
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(3) Determine whether plantibodies are transported across the vaginal epithelium; this 
mechanism would be a safety concern because, if transported, the mabs could potentially 
carry HIV into the tissues or enter the systemic circulation. 
 
 
MATERIALS & METHODS 
Neutralization assays with plant-derived mAbs 
The TZM-bl HeLa cell line, engineered to express CD4, CXCR4, and CCR5 with 
luciferase and beta-galactosidase reporter genes, was used for HIV neutralization assays 
(sourced from the NIH AIDS Research and Reference Reagent Program). Cell 
propagation media was DMEM 1X high glucose, with 10% heat-inactivated FBS 2% 
Penicillin/Streptomycin solution, 1% 2 mM L-Glutamine, 1% HEPES (all from Life 
Technologies). Neutralization assays were carried out by incubation of virus (500IU/well 
Q23-T/F strain from Dr. Manish Sager) with antibody at decreasing concentrations for 1 
hour and then adding TZM-bl cells (10,000 cells / well). Antibody was pipetted into wells 
starting at 1µg/ml with serial 2-fold dilutions resulting in antibody titer concentrations of 
0.5µg/ml, 0.25µg/ml, 0.125µg/ml, 0.0625µg/ml, and 0.03125µg/ml. Black-walled, clear 
bottom, tissue culture treated 96-well plates (Fisher) were used to incubate the assay for 
48 hours. The assay was developed using the Galacto-light plus system (Applied 
Biosystems) according to kit protocols (20µl lysis buffer, 70µl substrate, 100µl 
accelerator solution). A Synergy HT (Biorad) plate reader was used to read the developed 
96-well plate assay for luminescence levels. Experiments were run in triplicate. 
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Cynomolgus macaque vaginal lavage antibody test  
Cynomolgus macaque cervicovaginal lavages (CVLs) were obtained from Dr. 
Francois Villanger (Emory University). CVLs were collected prior to antibody treatment 
from 6 macaques to serve as baseline controls. Macaques were then treated with 2ml of 
HEC gel containing 1.25mg of VRC01-N, and then CVL was collected 4-hours after 
treatment. The macaques were allowed to rest and then treated with 1.25mg of VRC01-N 
with CVLs collected after 24-hours. The macaques were then rested again and treated 
with 1.25 mg of VRC01-N with CVLs collected after 72-hours. The entire process was 
further repeated with 5mg and 20mg concentrations of VRC01-N also in 2ml of HEC gel. 
CVL samples were tested in a neutralization assay, using virus (500IU/well of HIV-1 
Q23-T/F strain from Dr. Manish Sager), TZM-bl cells (10,000 cells/well), and 25µl or 
50µl of CVL sample diluted to 1:4 or 1:8. Virus and CVL sample were incubated for 1 
hour before cells were added. Black-walled, clear bottom, tissue culture treated 96-well 
plates (Fisher) were used to incubate the assay for 48 hours. The assay was developed 
using the Galacto-light plus system (Applied Biosystems) according to kit protocols 
(20µl lysis buffer, 70µl substrate, 100µl accelerator). A Synergy HT (Biorad) plate reader 
was used to read the developed 96-well plate assay for luminescence levels. Each 
experiment was run in at least triplicate. 
 
Pharmacokinetic of monoclonal antibody transport across MatTek Epivaginal 
Tissue 
 To study the pharmacokinetics of monoclonal antibody transport across the 
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vaginal epithelium, the MatTek Epivaginal tissue model (VEC-100, Ashland, MA) was 
used. The tissue is a fully stratified vaginal epithelial layer, grown on tissue culture 
inserts in 24-well tissue culture plates (Ayehunie et al. 2006). The tissue was incubated in 
proprietary MatTek media (MatTek Corporation) at 37˚C. Monoclonal antibody was 
added to the apical side, and basal supernatant was collected after 3-12 hours and tested 
for antibodies using the Abcam IgG Human ELISA Kit (Abcam). Some experiments 
were conducted under low pH conditions by adjusting MatTek media to pH 6.0 using 
HCl. In other experiments, inflammatory conditions were simulated by treating, tissues 
with TNF-alpha (50µl of a 10µg/ml concentration) for 24-hours prior to loading of Mabs. 
To measure the inherent permeability of the tissues, 10µl of 0.005g/ml sodium 
fluorescein was concurrently added to the tissues, and the amount that crossed into the 
basolateral supernatant was measured on a fluorometer. After incubation with the mabs, 
tissue was fixed in formaldehyde embedded in paraffin wax, and sectioned for staining. 
Four steps of Pro-Par submersion, three steps of 100% ethanol submersion, one step of 
95% ethanol submersion, and one step of 70% ethanol submersion was used to de-wax 
the tissue prior to staining, each step carried out for approximately 5 mins. A 1:10 
dilution of primary mouse anti-human IgG was applied to the tissues for 1 hour of 
incubation. Tissue was washed with 10% Tris buffer, and then incubated in the dark with 
secondary donkey anti-mouse Cy3 labeled antibody for 30 mins at antibody 
concentration of 1:1,000. Tissue was then counter-stained with anti-fade DAPI solution 
(Vector Labs). Follow-up staining was done on sections using an enzymatic stain, 
treating first with primary anti-IgG antibody (DAKO; diluted 1:50, 1 hour incubation), 
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followed by streptavidin-alkaline phosphatase (DAKO) for 20 mins, and developed with 
a DAKO proprietary substrate kit. Substrate development was halted with distilled water 
and sections were counterstained with hematoxylin. 
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RESULTS 
Specific Aim 1: Mab-N Neutralization Efficacy 
The plantibody VRC01-N effectively neutralized HIV Q23 virus at a concentrations >0.5 
µg/ml (Figure 2). 
 
 
Figure 2. Mapp VRC01-N mAb neutralization of Q23 transmitter/founder HIV 
strain. Varying concentrations of Mapp VRC01-N mAb were incubated with Q23 virus 
for one hour, then the mixture was added to TZM-bl cells and cultured for 48 hours. An 
antibody concentration of 1µg/ml of mAb inhibited HIV infection by 83%. The 
neutralization assay was carried out in triplicate. The data point labels represent the mean 
value of the triplicates. 
 
The NIH45-46 mAb was more effective at inhibiting HIV infection in the TZM-bl assay 
than VRC01 (Figure 3). This was expected as NIH45-46 is a newer construct of a mAb 
that used VRC01 as a basis for improvement. This suggests that if Mapp were able to 
produce NIH45-46 in nicotiana and use it in place of VRC01, it could increase the anti-
HIV efficacy of the microbicide product.  
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We were able to use the VRCO1 antibody dose response as a standard curve for the  
macaque cervicovaginal lavage assays (described below).  
   
Figure 3. NIH45-46 mAb neutralization of Q23 transmitter/founder HIV strain  
As a comparison and positive control for Mapp VRC01-N, NIH45-46 was used in the 
assay. As a modified, enhanced version of VRC01, NIH45-46 shows improved 
neutralization capabilities against the Q23 transmitter/founder HIV strain. At a 
concentration of 1µg/ml of mAb, 98% of the virus was inhibited. NIH45-46 showed 
improved neutralization capabilities at similar doses with Mapp VRC01-N. 
Neutralization assay was carried out in triplicate. The data point labels represent the mean 
value of the triplicates. 
 
PGT136 and PG135 were used as negative controls for both VRC01-N and NIH45-46. 
Results of neutralization assays of PGT136 and PGT135 (Figure 4 and Figure 5) showed 
that these antibodies were not inhibiting, which was expected, as they are known not be 
effective in neutralizing HIV.   
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Figure 4. PGT135 mAb neutralization of Q23 transmitter/founder HIV strain. 
PG135 mAb used as a negative control in the assay. PG135 is known not to neutralize 
this specific HIV strain. Results show that PG135 is not neutralizing at any concentration 
of mAb titer. The neutralization assay was carried out in triplicate. The data point labels 
represent the mean value of the triplicates. 
 
 
 
Figure 5. PGT136 mAb neutralization of Q23 transmitter/founder HIV strain. 
PG136 was used as a second negative control in the assay. PG136 is known not to 
neutralize this specific HIV strain. Results show that PG136 is not neutralizing at any 
concentration of mAb titer. The neutralization assay was carried out in triplicate. The 
data point labels represent the mean value of the triplicates. 
 
8.76 
-4.31 
-1.20 
3.17 2.59 
13.76 
-6.00 
-4.00 
-2.00 
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
14.00 
16.00 
0 0.2 0.4 0.6 0.8 1 1.2 
%
 in
hi
bi
tio
n 
Ab titer µg/ml 
PGT135 Mab HIV Neutralization 
4.32 
-3.31 
-10.31 
7.78 
-6.84 
3.02 
-15.00 
-10.00 
-5.00 
0.00 
5.00 
10.00 
0 0.2 0.4 0.6 0.8 1 1.2 
%
 in
hi
bi
tio
n 
Ab titer µg/ml 
PGT136 Mab HIV Neutralization 
 34 
Specific Aim 2: Cynomolgus macaque cervicovaginal lavage antibody test  
 
 Some of the CVLs obtained for baseline reference from macaques had innate 
inhibiting ability against HIV virus. The CVLs collected 4 hours following 1.25mg mAb 
dosing neutralized virus by near 100% (Figure 6), with just one macaque neutralizing at 
approximately 75%. However with increased doses at 5mg and 20mg, all the CVLs were 
able to neutralize cell-free virus at nearly 100% efficacy.  
 
 
Figure 6. MAb VRC01-N neutralization of Q23 transmitter/founder HIV from 6 
Cynomolgus macaque cervicovaginal lavage samples collected after 4-hours of 
antibody application at varying concentrations. Results show baseline untreated CVLs 
having moderate innate inhibition activity. CVLs from macaques treated with 1.25mg, 
5mg and 20mg of VRC01 mab-N very effectively neutralized HIV.  
 
These results were expected, as these doses were much higher than the 1µg/ml of Mab-N 
shown to be effective in the first experiment. Examination of the results from CVLs that 
were collected at the 24-hour time point from all concentrations of administered Mab-Ns 
however, showed unexpected data (Figure 7). 
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Figure 7. MAb VRC01-N neutralization of Q23 transmitter/founder HIV from 6 
Cynomolgus macaque cervicovaginal lavage samples collected after 24-hours of 
antibody application at varying concentrations. The Baseline CVLs again showed 
innate inhibition abilities however assay results showed very little inhibition for CVLs 
collected 24-hours later for doses of 1.25mg, 5mg, and 20mg. Results suggest possible 
increase in infection of TZM-bl cells. 
 
What we expected was decreased neutralization capabilities given the longer time point. 
However, from assay results, what can be seen are not only decreased neutralization 
capabilities but in some macaques the CVLs increased viral infectivity. Increased viral 
infection was seen as negative inhibition (luminescence was higher than the positive 
control wells in the assay). Figure 7 has some data omitted due to evidence of cell 
toxicity during assay incubation. The TZM-bl cell line contains the beta-galactosidase 
reporter gene and thus when used in conjunction with the Tropix beta-galactosidase 
system, would result in luminescence upon successful viral infection. Cell toxicity or cell 
death would result in artificially low luminescence or no response to the luminescence 
developing substrate at all and thus the reason for removal of a few data points in Figure 
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7. Only one macaque (8C75) showed HIV neutralization at the 24 hour time point, and 
only at the highest dose of Mab tested. 
 
 
 
Figure 8. MAb VRC01-N neutralization of Q23 transmitter/founder HIV from 6 
Cynomolgus macaque cervicovaginal lavage samples collected after 72-hours of 
antibody application at varying concentrations; assay carried out twice. Baselines in 
this assay run did not show any innate inhibition affects. In the 1.25mg and 5mg dose 
samples, increased infection of TZM-bl cells was observed. In the samples of 20mg 
doses, results indicate some inhibition is occurring but observations of assay showed cell 
toxicity, which would indirectly and incorrectly suggest inhibition. 
 
 
Figure 8 show HIV neutralization of CVLs collected 72 hours after Mab treatment.  
Macaque 8C75, and two others showed HIV neutralization at the highest mAb dose, 
others showed a tendency for increased viral infection. It is unclear as to the reasons of 
why this may be occurring. Figures 9 through 11 show CVL neutralization data when 
tested at a dilution of 1:8. 
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Figure 9. MAb VRC01-N neutralization of Q23 transmitter/founder HIV from 6 
Cynomolgus macaque cervical vaginal lavage samples collected after 4-hours of 
antibody application, diluted 1:8. Results show baseline samples again having innate 
inhibition of virus. Most CVLs from dosing of 1.25mg, 5mg, and 20mg of antibodies 
maintain inhibiting activity against virus. Some data were excluded due to TZM-bl cell 
toxicity. 
  
Figure 9 shows that the mabs in the CVLs retained neutralization activity at the 4 hour 
time point. Figure 10 shows neutralization data for macaque CVLs collected at the 24- 
hour time point and diluted 1:8. The CVLs showed less neutralizing ability at the higher 
dilution, and again showed evidence of increased viral infection or negative inhibition, 
where detected luminescence was greater the positive control wells. 
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Figure 10. MAb VRC01-N neutralization of Q23 transmitter/founder HIV from 6 
Cynomolgus macaque cervical vaginal lavage samples collected after 24-hours of 
antibody application at varying concentrations, diluted 1:8. Results show baseline 
CVLs having minor inhibitory effects. CVLs from macaques treated with 1.25mg of mAb 
showed both successful inhibition of virus and increased viral infection. CVLs from 
macaques treated with 5mg and 20 mg of mAb show similar results. Some data were 
excluded due to TZM-bl cell toxicity. 
 
 
 
Figure 11. MAb VRC01-N neutralization of Q23 transmitter/founder HIV from 6 
Cynomolgus macaque cervical vaginal lavage samples collected after 72-hours of 
antibody application at varying concentrations, diluted 1:8. Results show baseline 
CVLs having some innate inhibition. CVLs from macaques treated with 1.25mg of mAb 
showed both inhibition and increased viral infection. CVLs treated with 5mg and 20mg 
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showed similar results of exhibiting both inhibition and increased viral infection. 
Macaque 8C75 shows high viral inhibition in this assay. 
 
 
 
Figure 12 shows a comparison of assay results for CVLs from individual 
macaques collected at the 4-hour time point and tested at 1:4 and 1:8 dilutions. The data 
for each macaque show neutralization occurring consistently in an upward trend 
coinciding with increased dose of Mab-N, with the 1:8 dilution data showing less 
inhibition for certain macaques such as 6C109, 7C126, and 8C4-32. For some macaques 
such as 7C40, 8C75, HBC41, the higher dilution factor had less effect on neutralization 
capabilities and at higher doses such as 5mg and 20mg, the dilution had no effect on 
inhibition. This was an expected result as given the short time point at which CVLs were 
collected, the Mab-Ns were expected to retain their efficacy at all doses.  
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Individual Macaque Comparision of CVLs collected at the 4-hour time point, 1:4 
and 1:8 dilutions. 
 
A.       B. 
  
 
C.       D. 
  
 
E.       F. 
  
 
Figure 12. Comparison of individual macaque neutralization assay results, 1:4 
versus 1:8 dilutions. CVLs were harvested 4-hours post treatment. Data on individual 
macaque samples are compared against each other with samples diluted 1:4 and 1:8. The 
same macaques showed similar neutralizing trends and capabilities even at diluted 
amounts.  
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Figure 13 shows a comparison of data from CVLs at the 24-hour time point: two 
1:4 dilution assays and one 1:8 dilution assay. It is here at the 24-hour time point that the 
increased viral infection is seen. Comparison of individual monkeys, specifically Figure 
13A, B, C, D, shows similar trends between the three assays suggesting that what is 
causing the increased infection is sample specific. Furthermore, where increased viral 
infection is observed in Figure 13A, B, C, D, the effect is decreased at the 1:8 dilution. 
The repeated pattern strongly supports the accuracy of the data. Figure 13E, and F, show 
data that is less uniform.  
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Individual Macaque Comparision of CVLs collected at 24-hour time points, 1:4 
dilution to 1:8 dilution.. 
 
A.      B. 
 
C.      D. 
  
E.      F. 
 
Figure 13. Comparison of individual macaque neutralization assay results. Two 
runs of 1:4 dilutions and 1 run of 1:8 dilutions. CVLs were harvested 24-hours post 
treatment. Three macaques showed data points that were similar in neutralization 
capabilities. The other three macaques showed data points that were not similar in 
neutralization capabilities. Some data from the post 24-hour treated samples showed 
increased viral infection. One data point from macaque HBC41 specifically showed 
100% neutralization without observed cell toxicity. Other data points were excluded due 
to observed cell toxicity signifying unreliable data. 
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Figure 14 shows a comparison of data from CVLs collected at the 72-hour time 
point: two 1:4 dilution assays and one 1:8 dilution assay. Individual macaques show 
similar trends of neutralization capability and similar trends of increased viral infection, 
specifically in Figures 14A, C, E, F.  
Individual Macaque Comparision of CVLS collected at the 72-hour time point, 1:4 
and 1:8 dilutions. 
 
A.      B. 
  
C.      D. 
   
E.      F. 
  
 
Figure 14. Comparison of individual macaque neutralization assay results. Two 
runs of 1:4 dilutions and 1 run of 1:8 dilutions. CVLs were harvested 72-hours post 
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treatment. Macaques 6C109, 7C40, and 8C75 showed data that followed a neutralization 
trend given the two runs of 1:4 dolutions and 1 run of 1:8 dilutions. Macaques 7C126, 
8C4-32, and HBC41, showed data that did not show neutralization trends between the 
tested 1:4 and 1:8 dilutions. Again all samples showed data points in which increase viral 
infection occurred. 
 
Specific Aim 3: Mab-N Pharmacokinetics in MatTek Epivaginal Tissue Model 
 
Preliminary tests of Mab-N ability to traverse the vaginal epithelium at both 
neutral and pH 6 suggested very little transfer, 0.03% of loaded amount (Figure 15). At 
pH 6, because the absorbance reading of both VRC01-N samples and one 4E10-N sample 
was greater than the upper limit of the standard, the data suggests that at least 0.03% was 
transferred. A larger experiment was conducted repeating these preliminary studies and 
also including TNF-alpha treated tissue, while incubating the tissues with antibodies for 
24-hours. Figure 16A and 16B show again that at neutral pH and both pH 6, both Mab-N 
treated tissue samples showed consistent transfer of approximately 0.03%. 
 
 
Figure 15. Percent transfer of 25ug of IgG added to apical reservoir detected in 
basal supernatant after 3-hours. ELISA results from recovered basal supernatant after 
3-hours suggests a transfer of 0.03% of loaded IgG. At neutral pH, both Mab-Ns did not 
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exceed 0.03% transfer of IgG loaded. At pH 6.0, both VRC01-N treated tissue exceeded 
the highest known standard readings denoted by the asterisk. At pH 6.0, only one 
VRC01-N treated tissue suggested IgG transfer exceeding 0.031%. Thus the asterisk 
noted data suggests that at least 0.031% transfer occurred. 
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C 
 
 
Figure 16. Percent transfer of 25µg of IgG added to apical reservoir detected in 
Basal supernatant after 24-hours. Panel A shows that at 24-hours, levels of both 
VRC01-N and 4E10-N in the basal medium do not exceed 0.032% of originally loaded 
amounts. When the experiment was conducted at pH of 6.0 (Panel B), both Mab-N’s 
again did not exceed 0.032% transfer of apically loaded IgG. When tissue treated with 
TNF-alpha was used (Panel C), VRC01-N transfer was consistent at 0.032% while 4E10-
N showed a lower percentage of IgG transfer at 0.022% and 0.015%.  
 
When TNF-alpha treated tissue was used (Figure 16C), 0.3% of VRC01-N was 
detected in the basolateral supernatant, while levels of 4E10-N were lower. These data 
suggest that minimal amounts of Mab-Ns cross the vaginal epithelium. As a comparison, 
tissue was treated with 5mg/ml and 1mg/ml of IgG purified from human serum for 24 
hours (Figure 17). Higher amounts of IgG were observed in basal supernatants, possibly 
due to the longer incubation time.  
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Figure 17. Percent transfer of IgG added to apical reservoir detected in basal 
supernatant after 24-hours. The experiment was carried out using purified IgG using 
super-concentrated amounts of purified human-IgG. The data shows 5mg/ml transferring 
at approximately 0.3% across while 1mg/ml unexpectedly transferring higher at 0.371% 
and 0.969%.  
 
A larger experiment was conducted this time with a 3-hour time point and 24-
hour time point Figure 18). At 3-hours, with high concentrations of purified human IgG 
and 4E10-N, far lower amounts of IgG transferred across the tissue (approximately 
0.005%). One tissue sample of human-IgG loaded with a 1mg/ml concentration managed 
to show percent transfer across tissue at 0.035%, closer to previous results. At 24-hours, 
the transfer of IgGs across tissue was inconsistent. At the highest concentration of 
5mg/ml the percent transfer of IgG was in 0.05% and 0.095%. Unexpectedly the 1mg/ml 
showed greater transfer at 0.114%, 0.468%, and 0.460%. Again it was unexpected to see 
the lower concentrated condition show greater transfer. These results, however, show 
some correlation with preliminary results from Figure 17. At 24-hours, the 4E10-N, 
showed consistent of transfer of IgGs around ~0.03% with one sample being 0.045%. 
0.28% 0.31% 
0.371% 
0.969% 
0.00% 
0.20% 
0.40% 
0.60% 
0.80% 
1.00% 
1.20% 
IgG 5mg/ml IgG 5mg/ml IgG 1mg/ml IgG 1mg/ml 
%
 T
ra
ns
fe
r 
Tissue IgG Treatment Condition 
(24hr) % transfer of 50µl of apically loaded Hu-IgG 
 48 
This was inline with previous results from Figure 15,16. 
A.
B.
 
 
Figure 18. Percent transfer of IgG added to apical reservoir detected in basal 
supernatant after 3 hours and 24-hours using purified human-IgG at 5mg/ml and 
1mg/ml concentrations. The data here for both 3-hour and 24-hour incubation times 
(Panel A and Panel B) show the 5mg/ml conditions transferring at far lower amounts than 
Figure 17. Figure 18A shows 3-hour incubation time with maximum transfer of IgG for 
one tissue using 1mg/ml concentration IgG not exceeding 0.03%. At 3-hours, the data 
indicate that very little transfer of IgG occurs. At 24-hours the 5mg/ml loaded 
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concentration showed transfer of 0.05% and 0.09%, while the 1mg/ml loaded 
concentration unexpectedly showed greater IgG transfer. IgG transfer was greater at the 
24-hour time point than at 3-hours. 
 
 
In order to rule out any inherent leakage of the tissue itself the experiments 
conducted in Figure 18 were carried out concurrently with addition of 10µg of 
0.005mg/ml sodium-fluorescein, a dye that detects tissue leakage. Figure 19 show results 
from fluorescence readings of collected basal supernatants. At the three-hour time point, 
the well that showed the most IgG transfer also had the most sodium fluorescein transfer, 
indicating that this tissue was leaky. At the 24-hour time point, much more sodium 
fluorescein crossed over indicating that the tissues were much leakier at that time point, 
and that Ig crossover at the 24-hour time point may be nonspecific.  
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A. 
 
B. 
 
 
Figure 19. Percent transfer of 50ug of Sodium-Fluorescein loaded apically, 3-hour 
and 24-hour time points. The data show that at 3-hours the minimum transfer was 
0.087% while the maximum was 1.31%. At 24-hours the minimum was 1.85% while the 
maximum was 9.30%. 
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The tissue that had been treated with Mabs was processed for immunohistologic detection 
of IgG in the tissues. Figure 20 shows data for Mab-N 4E10.  
A.      B. 
 
Figure 20. Anti-Human-IgG stain for Mab-N 4E10 in VEC tissue. 
Immunohistochemistry showed Mab-N concentrated on the apical surface, but no 
penetration beyond the stratum corneum layer. Panel A is immunohistochemistry using 
alkaline phosphatase enzyme stain (positive Mabs stain purple), while Panel B is 
immunohistochemistry utilizing a Cy3 fluorescence stain (positive Mabs stain red) with 
nuclei counterstained with DAPI. 
 
Figure 20A and B show 4E10-N concentrated along the apical surface of the 
vaginal epithelial model, but none was detected deeper in the tissue. Figure 21 shows 
similar data with VRC01-N. Both Figure 20 and Figure 21 confirm the ELISA data 
showing very little transport of IgG across the vaginal epithelium. 
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A.      B. 
 
Figure 21. Anti-human IgG stain for VRC01-N. Panels A and B show two stains of the 
bright purplish-red stained VRC01-N concentrated in the superficial layers of EpiVaginal 
tissue model. VRC01-N does not penetrate below the stratum corneum of tissue. 
 
 
Figure 22 presents immunohistology for tissue that was not exposed to IgG (negative 
control) showing that media does not contain IgG and also that the primary antibody used 
to detect the presence of IgG does not bind nonspecifically to the tissue. Figure 22C 
shows immunohistology of experiment loaded with Human-IgG as a positive control 
showing specific binding of primary antibody to IgG in the stratum corneum. 
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A.      B. 
 
 
C. 
 
 
Figure 22. Immunohistology for experiment control and staining control. A. 
Immunohistology for experiment control and B. staining negative control do not show 
any non-specific staining of tissue. C. Positive control using human serum showing no 
penetration of human-IgG below stratum corneum in enzyme staining. (Human IgG 
shown by dark purple stain). 
 
We also performed immunohistology to detect the IgG transport molecule, FcRn, in 
EpiVaginal tissue, as was described in the report by Liu wet al (2011). We detected 
FcRN in the basal epithelial cells, but not in cells higher in the epithelium. 
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Figure 23. FcRn localization in MatTek EpiVaginal Tissue Model. Immunohistology 
shows FcRn staining (red) localized in the basal layer of epithelium above the lamina 
propria. The tissue is counterstained with hematoxylin. Photo courtesy of Dr. Jeffrey 
Pudney. 
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DISCUSSION 
 
 
 Recent strategies to block HIV transmission have been focusing on topical 
microbicides. As a part of a larger project, the specific aims of this thesis focused on 
investigating the efficacy of Mab-Ns VRC01 and 4E10-N in in-vitro and ex-vivo HIV 
infection assays. These studies aimed to characterize the efficacy of Mab-Ns in three 
separate experiments. In the first experiment, Mab-N neutralizing efficacy was assayed 
against cell-free virus. In the second experiment, Mab-Ns in CVLs were tested against 
cell-free virus. CVLs were collected after administration of Mab-Ns in varying 
concentrations to the vaginal lumens of Cynomolgus macaques for a specific duration of 
time. Lastly, the pharmacokinetics of Mab-Ns was studied on an EpiVaginal tissue model 
to insure its inability to penetrate the epithelial layer and enter into system circulation. 
Our data show that the neutralizing MAb-Ns performed similarly to Mabs 
produced by traditional methods and support the continued development of Nicotiana 
derived MAbs in order to seek a more cost effective methods of production. In terms of 
retention of activity in the vaginal environment, after four hours the mAbs were able to 
neutralize free virus. However, beyond the four-hour time point antibody activity was 
reduced and in some cases the assay showed increased viral infection. The increased viral 
infection was not a result that was expected. This could possibly be attributed to TZM-
bl's containing a higher ratio of CD4:CCR5 receptors rather than natural PBMC’s which 
would be an inherent issue with the assay model. Unfortunately an ideal assay model that 
would better represent PBMCs without the variability of multiple donors does not exist. 
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The TZM-bl assay at this point in time offers the most consistency for carrying out 
neutralization assays. 
 There are some thoughts as to why increased viral infection is being observed in 
CVLs collected at the 24-hour and 72-hour time points, but not at the 4 hour time point.  
It is possible that the Mab-Ns are eliciting the release of immune response molecules 
such as proinflammatory cytokines from macaques that may be increasing viral infection. 
It is also possible that what we are interpreting as increased viral infection is actually and 
artifact. One possibility is that the CVLs collected at the 24- and 72-hour time points 
contain microflora that produce enhanced luminescence readings. These microflora could 
be missing from the 4-hour samples, because collection of baseline samples entails 
washing the vaginal cavity with saline. It is also possible that the data are evidence of a 
mechanisms known as antibody dependent enhancement of HIV-1 virus (Willey et al., 
2011). Further research is needed to determine the reason for the observed viral 
enhancement at the 24- and 72-hour time points. 
  Our data show that 4E10-N, VRC01-N, and human-IgG will cross the MatTek 
vaginal epithelial model, but it occurs to a very small degree within a 3-hour time frame, 
and observed transfer at 24 hours could be due to nonspecific leakiness in the model. The 
ELISA data is confirmed by immunohistochemistry showing that Mab-Ns are not 
transferred across the tissue. The Mab-Ns did concentrate in the stratum corneum (top 
most layer) of the vaginal epithelium, but no evidence of internalization was observed. 
Based on vaginal epithelial histology, the stratum corneum is comprised of cells that have 
terminally differentiated to lack nuclei and organelles. Cells at this level are not expected 
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to contain cell functions able to transport antibody molecules. Furthermore, FcRn (the 
IgG transport molecule) was located only in the basal layers of the epithelium. Since it is 
not possible for Mab-Ns to penetrate to the depth of tissue where FcRn is expressed due 
to tight junctions between the cells, FcRn could not play a role in any active transport of 
IgG from the apical to basal direction. Our data provide evidence that Mab-Ns do not 
cross the vaginal epithelium and are safe to use as topical microbicides. 
Future directions that stem from this project would be to test the ability of 
Nicotiana derived monoclonal antibodies to block SIV transmission in simian models 
that would best replicate human physiology. Upon success of those experiments, Phase 1 
clinical trials to prove safety of the antibodies in women could be conducted, followed by 
Phase 2 and Phase 3 (clinical efficacy) trials. Potential applications include films, rings or 
other types of drug reservoirs that could slowly release the Mab-N cocktails without the 
need for frequently repeated application. This would negate the non-compliance issues of 
previous microbicide trials such as those that plagued the VOICE study, and offer easy 
use for consumers in an over the counter setting.  
 
Conclusion 
 In summary, we have provided data supporting the efficacy of nicotiana-derived 
monoclonal antibodies in comparison to those produced by conventional methods. Data 
from cervicovaginal lavages obtained from macaques that had been treated with 
nicotiana-derived monoclonal antibodies showed efficacy in physiological conditions at 
the 4-hour time point. Our data strongly confirm that nicotiana-derived monoclonal 
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antibodies are not transferred across the vaginal epithelium in an apical to basal direction 
to potentially enter the systemic circulation. Our work supports the continued study and 
pursuit of nicotiana-derived monoclonal antibodies as a topical microbicide to prevent 
the transmission of HIV-1. 
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